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Background
Involvement of community level stakeholders in the
future HIV vaccine trials is essential to ensure that rights,
views, concerns, needs and expectations of the target pop-
ulation are fully taken into account in all phases of their
implementation. We carried out a multicomponent situa-
tion analysis in two future urban sites in Burkina Faso to
identify the proper way to setting up a CAB competent to
accompany the trials.
Methods
HIVTAB project is funded by European and Developing
Countries Clinical Trials Partnership in Tanzania and
partly by French National Agency for AIDS Research
(ANRS) in Burkina Faso to strengthen research capacities
in preparation to future HIV vaccine trials. Social science
methods were applied in recruiting of 23 key informants
for in-depth interviews and 03 focus groups discussions
between investigators and representatives of community-
based NGOs were conducted.
Results
Since 2007 Sidaction provided support to a Network of
NGO'S involved in protection of research participants.
Also ANRS supports clinical trials in Burkina properly
shaped by ANRS ethics charter. The community's leaders
want the New CAB to be built around Sidaction initiative.
They also prefer one CAB for all the research projects fully
or partly managed by the ANRS in Burkina Faso. This CAB
will provide impartial witnesses and advice on research
design, implementation and dissemination of findings to
the community. To protect the confidentiality of studies
participants, all members of CAB will sign a confidential-
ity agreement. The community's representatives want to
charge all the projects, particularly the HIVTAB-Project for
all the fees related to the implementation of the CAB.
Conclusion
The EDCTP-funded HIVTAB project, by establishing a
CAB will enhance community involvement in preparation
for future HIV vaccine trials. Nevertheless the funding
sources of this CAB and the qualification of community
representatives need further discussions and clarifications
to not jeopardize its independence and credibility.
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